Priming experiments with a control peptide frequently presented on HLA-B*18 in both, tumor and benign tissues (peptide presentation > 90% in HLA-matched sources), confirmed MM-specificity of the induced T-cell responses (Fig. 2b, Supplemental Table 2). The gene discussed is HLA-B; the disease is neoplasm.